The CXCR5 receptor, a new target in inflammation?

[摘要]：

A method of treating CXCL13-mediated inflammatory diseases by the co-administration of a CXCL13 antagonist and a TNF-alpha. antagonist is claimed. Their use is claimed to provide methods of treating asthma, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis and systemic lupus erythematosus. The reported activity of such combinations in animal models provides evidence for the CXCR5 chemokine receptor as a potential drug target in such diseases.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内